Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR1A | P08908 | 7/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18952739 | 0.98 | HTR2C (0.47) | SLC18A3SIGMAR1HTR2CHTR1ASLC6A2 | |
| SCHEMBL1741786 | 0.86 | HTR3A (0.42) | SLC18A3SIGMAR1HTR2CHTR1ASLC6A2 | |
| SCHEMBL29889400 | 0.86 | HTR3A (0.42) | SLC18A3SIGMAR1HTR2CHTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL2654549 | 0.85 | HTR3A (0.41) | HTR2CHTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL935722 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL29162507 | 0.79 | OPRL1 (0.36) | KDM4E | |
| SCHEMBL3783902 | 0.79 | HRH3 (0.44) | SLC18A3SIGMAR1HTR2CHRH3 | |
| SCHEMBL31736812 | 0.77 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR2CHRH3 | |
| SCHEMBL1444138 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL676894 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11352357-B2 | Cycloalkylurea derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-6114522-A | DEPROTONIZING A BEZOXAZEPINE DERIVATIVE WITH A BASE, REACTING THE DEPROTONIZED PRODUCT WITH A PHOSPHATE HALIDE TO PRODUCE AN INTERMEDIATE, REACTING INTERMEDIATE WITH A COMPLEX OF HALOGEN AND TRIALKYL OR ARYL PHOSPHINE | SUNTORY LIMITED (JP) | 2000-09-05 | — | — | US | disclosed |
| CN-1236363-A | Process for production of 4-substituted-3-halogeno-1, 4-benzoxazepine derivative and salts thereof | SUNTORY LTD (JP) | 1999-11-24 | — | — | CN | disclosed |
| EP-0925288-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999003847-A1 | PROCESS OF PRODUCTION OF 4-SUBSTITUTED-3-HALOGENO-1,4-BENZOXAZEPINE DERIVATIVE AND SALTS THEREOF | SUNTORY LIMITED (JP) | 1999-01-28 | — | — | WO | disclosed |
| EP-0640599-B1 | 4-Aminopyrimidine derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
| US-5525604-A | USED IN PREVENTION OR TREATMENT OF THROMBOSIS, ARTERIOSCLEROSIS, ISCHEMIC HEART DISEASES, GASTRIC ULCER OR HYPERTENSION | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-06-11 | — | — | US | disclosed |
| CN-1109055-A | 4-aminopyrimidine derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-09-27 | — | — | CN | disclosed |
| EP-0640599-A1 | 4-Aminopyrimidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | SLC18A3 919/4885SIGMAR1 2679/4885HTR2C 235/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | SLC18A3 919/4885SIGMAR1 2679/4885HTR2C 235/4885 |
| US-11352357-B2 | Cycloalkylurea derivative | HCRTR2, HCRTR1, CRHR2 | SLC18A3 376/4885SIGMAR1 107/4885HTR2C 50/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | SLC18A3 3182/4885SIGMAR1 3512/4885HTR2C 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.